file,ref_number,ref_text,doi,doi_url,titleDoi,firstAuthDoi,author_similarity,title_similarity
experiments/glioblastoma_survival/ai_messages/high_complexity--generated_TP53_MGMT_medium_methylated,[1],"Levine AJ. 2020. Cell. p53: 30 years and 30,000 papers later.",10.2307/j.ctvwh8f9c.50,https://doi.org/10.2307/j.ctvwh8f9c.50,Mystery Woman Speaks 30 Years Later,,0,57
experiments/glioblastoma_survival/ai_messages/high_complexity--generated_TP53_MGMT_medium_methylated,[2],"Hegi ME, et al. 2005. N Engl J Med. MGMT gene silencing and benefit from temozolomide in glioblastoma.",10.3410/f.718384246.793495041,https://doi.org/10.3410/f.718384246.793495041,Faculty Opinions recommendation of MGMT gene silencing and benefit from temozolomide in glioblastoma.,Gilbert,10,80
experiments/glioblastoma_survival/ai_messages/high_complexity--generated_TP53_MGMT_medium_methylated,[3],Cancer Genome Atlas Research Network. 2008. Nature. Comprehensive genomic characterization defines human glioblastoma genes and core pathways.,10.1038/nature07385,https://doi.org/10.1038/nature07385,Comprehensive genomic characterization defines human glioblastoma genes and core pathways,The Cancer Genome Atlas Research Network,95,100
experiments/glioblastoma_survival/ai_messages/high_complexity--generated_TP53_MGMT_medium_methylated,[4],"Furnari FB, et al. 2007. Genes Dev. Malignant astrocytic glioma: genetics, biology, and paths to treatment.",10.1101/gad.1596707,https://doi.org/10.1101/gad.1596707,"Malignant astrocytic glioma: genetics, biology, and paths to treatment",Furnari,100,100
experiments/glioblastoma_survival/ai_messages/high_complexity--generated_TP53_MGMT_medium_methylated,[5],"Stupp R, et al. 2005. N Engl J Med. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.",10.1097/01.cot.0000289242.47980.f9,https://doi.org/10.1097/01.cot.0000289242.47980.f9,“Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma”,Stupp,100,100
